TY - JOUR
T1 - Role of adjuvant therapy in intermediate-risk cervical cancer patients – Subanalyses of the SCCAN study
AU - Cibula, David
AU - Akilli, Huseyin
AU - Jarkovsky, Jiri
AU - van Lonkhuijzen, Luc
AU - Scambia, Giovanni
AU - Meydanli, Mehmet Mutlu
AU - Ortiz, David Isla
AU - Falconer, Henrik
AU - Abu-Rustum, Nadeem R.
AU - Odetto, Diego
AU - Klát, Jaroslav
AU - dos Reis, Ricardo
AU - Zapardiel, Ignacio
AU - di Martino, Giampaolo
AU - Presl, Jiri
AU - Laky, Rene
AU - López, Aldo
AU - Weinberger, Vit
AU - Obermair, Andreas
AU - Pareja, Rene
AU - Poncová, Renata
AU - Mom, Constantijne
AU - Bizzarri, Nicolò
AU - Borčinová, Martina
AU - Aslan, Koray
AU - Salcedo Hernandez, Rosa Angélica
AU - Fons, Guus
AU - Benešová, Klára
AU - Dostálek, Lukáš
AU - Ayhan, Ali
N1 - Funding Information: This work was supported by grants from Charles University in Prague ( COOPERATIO , UNCE 204065 ), Ministry of Health of the Czech Republic ( MH CZ – DRO-VFN64165 ), and the Czech Health Research Council ( NV19-03-00023 ). The funding sources were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Publisher Copyright: © 2023 Elsevier Inc.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Objective: The “intermediate-risk” (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods: We analyzed data from patients with IR cervical cancer (tumor size 2–4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results: Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT−) and 418 (60.4%) received radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT− and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size ≥4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion: Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease-free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy.
AB - Objective: The “intermediate-risk” (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods: We analyzed data from patients with IR cervical cancer (tumor size 2–4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results: Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT−) and 418 (60.4%) received radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT− and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size ≥4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion: Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease-free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy.
KW - Adjuvant treatment
KW - Cervical cancer
KW - GOG criteria
KW - Intermediate risk
KW - Radial surgery
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85147455294&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ygyno.2023.01.014
DO - https://doi.org/10.1016/j.ygyno.2023.01.014
M3 - Article
C2 - 36706646
SN - 0090-8258
VL - 170
SP - 195
EP - 202
JO - Gynecologic Oncology
JF - Gynecologic Oncology
ER -